Medical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study
Medizinische Kosten eines postoperativen Delirs nach hochinvasiver Krebsresektion: prospektive Kohortenstudie
Japanese Journal of Clinical Oncology · 13.02.2026 · 56 (2) · 187-195
DOI: 10.1093/jjco/hyaf172 ↗Auf einen Blick
Bei 281 Erwachsenen nach hochinvasiver Krebsresektion war schweres Delir mit höheren FFS-Kosten verbunden. Für DPC-Kosten zeigte sich kein signifikanter Unterschied; SSD hatte keinen signifikanten ökonomischen Einfluss.
Fragestellung
Wie hoch ist die ökonomische Belastung von subsyndromalem Delir und schwerem Delir nach hochinvasiver Krebsresektion?
Methode
Prospektive Kohortenstudie mit 281 Erwachsenen nach hochinvasiver Krebsresektion; Bewertung von schwerem Delir und SSD; primärer Endpunkt waren DPC-Kosten.
Ergebnisse
55 Patient:innen (19,6 %) entwickelten schweres Delir. DPC-Kosten zeigten keinen signifikanten Mittelwertunterschied; totale FFS-Kosten waren bei schwerem Delir höher (Mittelwertdifferenz: US$2364, 95 %-KI US$122 bis US$4606).
Schlussfolgerung der Autor:innen
Schweres postoperatives Delir nach hochinvasiver Krebsresektion war mit höheren FFS-Ausgaben verbunden, während bei DPC-Kosten keine signifikanten Unterschiede beobachtet wurden.
Kernaussagen
- Schweres Delir trat bei 55 Patient:innen auf.
- FFS-Kosten waren bei schwerem Delir höher.
- SSD zeigte keinen signifikanten ökonomischen Einfluss.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 11.11.2025. Verfasst von Ryoichi Sadahiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psycho-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Delirium, Postoperative Complications, Neoplasms, Health Care Costs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS, Practical Research for Innovative Cancer Control Project, Japan Agency for Medical Research and Development.
Themen: Delir
Abstract (Originalsprache)
Background
Postoperative delirium (POD) is a common and serious complication, especially among older adults. The economic burden of POD, particularly in patients undergoing highly invasive cancer resection who are at high risk of delirium, remains unclear. We aimed to clarify the economic burden of subsyndromal delirium (SSD) and severe delirium in this population.
Methods
We prospectively enrolled 281 adults undergoing highly invasive cancer resection and evaluated the impact of severe delirium and SSD diagnosed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and the Delirium Rating Scale-Revised-98 severity scale. The primary outcome was diagnosis procedure combination (DPC) costs. Propensity score matching was performed to estimate the effect of delirium within a background-matched cohort, and generalized estimating equations with two-way cluster-robust standard errors were applied at both matched-set and patient levels. Sensitivity analyses were performed using direct medical costs (fee-for-service [FFS]).
Results
Fifty-five patients (19.6%) developed severe delirium. DPC costs showed no significant mean difference, whereas total FFS costs were significantly higher in severe delirium (mean difference: US$2364, 95%CI: US$122 ~ US$4606). Component analyses indicated higher costs for prescriptions, infusions, wound-related procedures, and laboratory tests. SSD had no significant economic impact.
Conclusion
Severe postoperative delirium after highly invasive cancer resection was associated with increased FFS expenditures, particularly for prescriptions, infusions, wound care, and laboratory tests, whereas no significant differences were observed in DPC costs. Findings underscore the importance of preventing severe delirium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psycho-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Immune Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- University of Exeter Medical School, St Luke's Campus, Heavitree Road, Exeter, Devon EX1 2LU, United Kingdom.
- Division of Biostatistical Research, Institution for Cancer Control/Biostatistics Division, Center for Administration and Support, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Graduate School of Public Health, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
- Division of Quality Assurance Programs, Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
ORCID-Profile: Ryoichi Sadahiro, Hiromichi Matsuoka
Förderung
- JSPS
- Practical Research for Innovative Cancer Control Project
- Japan Agency for Medical Research and Development
Zitieren
APA
Sadahiro, R., Koyama, R., Kuchiba, A., Wada, S., Shimizu, K., Yoshida, T., Aoki, K., Uezono, Y., Matsuoka, H., & Saito, E. (2026). Medical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study. Japanese Journal of Clinical Oncology, 56(2), 187-195. https://doi.org/10.1093/jjco/hyaf172
Vancouver
Sadahiro R, Koyama R, Kuchiba A, Wada S, Shimizu K, Yoshida T, et al. Medical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study. Japanese Journal of Clinical Oncology. 2026;56(2):187-195. doi:10.1093/jjco/hyaf172
BibTeX
@article{Sadahiro2026,
author = {Sadahiro, Ryoichi and Koyama, Riria and Kuchiba, Aya and Wada, Saho and Shimizu, Ken and Yoshida, Teruhiko and Aoki, Kazunori and Uezono, Yasuhito and Matsuoka, Hiromichi and Saito, Eiko},
title = {Medical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
volume = {56},
number = {2},
pages = {187--195},
doi = {10.1093/jjco/hyaf172}
}
EUVIMED